ASCPT NEWS

Final call for award nominations

Help ASCPT recognize excellence in our important field of clinical pharmacology and translational medicine by nominating someone who has excelled in the field or within a mentoring role for one of the ASCPT Awards.

The ASCPT Award Categories are:

- Leon I. Goldberg Early Investigator Award
- Henry W. Elliott Distinguished Service Award
- Gary Neil Prize for Innovation in Drug Development
- Oscar B. Hunter Career Award in Therapeutics
- Rawls-Palmer Progress in Medicine Award
- Sheiner-Beal Pharmacometrics Award
- Malle Jurima-Romet Mid-Career Leadership Award
- William B. Abrams Award in Geriatric Clinical Pharmacology
- Mentor Award

Recipients will be recognized at the opening session of the 2018 Annual Meeting in Orlando, FL, as well as throughout the meeting.

Visit www.ascpt.org for more information and criteria for each of the ASCPT Scientific Awards and to nominate a worthy colleague. The deadline to nominate is Thursday, June 1, 2017, 4:00 PM ET.

Submit your best science for consideration for ASCPT 2018

ASCPT calls upon our members to help create an Annual Meeting scientific program that draws more than 1,400 attendees to hear the latest in the field of clinical pharmacology and translational medicine. The Scientific Program Committee (SPC), Chaired by Peter H. O'Donnell, MD, welcomes submission of cutting-edge proposals for Workshops, Science at Sunrise, Symposia and Roundtables/Novel Format by the June 2, 2017, 4:00 PM ET deadline.

For the 2018 Annual Meeting, the SPC encourages proposals that:

- Include early career scientists as active co-chairs and/or speakers
- Include patients or patient advocates
- Allow for dynamic presentation formats
- Are developed by multiple Networks and/or Communities

The theme of the 2018 Annual Meeting is “Breaking Down Barriers to Effective Patient Care.” This theme refers to the essential contributions of clinical pharmacology to the development of today’s discovery into tomorrow’s medicine. Proposals will best align with the theme if they address use of clinical pharmacology methods to move a molecule through the phases of drug development or to refine or expand use postapproval. Possible topics include: target identification, translation from preclinical models to humans, early identification of safety signals, development of biomarkers and diagnostics, model-based drug development, identification of relevant patient subgroups, and utilization of real-world data.

View the Call for Proposals brochure online at www.ascpt.org for full details. Questions about submission can be sent to meetings@ascpt.org.

Plan now to attend the 2018 Annual Meeting

Planning for the 2018 Annual Meeting, to be held March 20–24 at the Hilton Orlando, Orlando, FL, is well underway, and we encourage you to mark your calendar for this top-notch event now. Features of the meeting will include an exhibit hall featuring products and services important to you, more than 300 scientific abstracts on display, two receptions, countless networking opportunities, and a program complete with State of the Art speakers and featured speakers culled from your ASCPT colleagues.

The 2018 will also feature three pre-conference events:

- Phase-0/Microdosing Stakeholder Meeting chaired by Tal Burt, MD, Burt Consultancy, LLC, and Le Vuong, PhD, LTV Consulting
- Pediatric Drug Development in Oncology: Challenges and Opportunities Chaired by Konstantina M. Vanevski, MD, Bayer HealthCare LLC, and Dionna Green, MD, US Food and Drug Administration
- Pharmacometrics Meets Health Economics: Quantitative Approaches in the Translation From Efficacy to Real-World Effectiveness and to Cost-Effective Patient Care Chaired by Jing Liu, PhD, Pfizer

ASCPT’s flagship journal, *Clinical Pharmacology & Therapeutics* (CPT), is working to offer more original research content in each monthly issue! Part of these efforts includes encouraging our ASCPT members to submit their original research to the journal for consideration. As an incentive to submit, any original research paper that has a member as first, last, or corresponding author will be sent for external review.

Consider submitting your next original research paper to CPT. Visit the CPT online at www.cpt-journal.com to view the full scope of the journal and for submission details. Questions about submission can be directed to cpt@ascpt.org.

**Help ASCPT Make It Ours, Make It Great**

At the 2017 Annual Meeting, Immediate Past President Julie A. Johnson, PharmD, announced an exciting initiative that is currently underway for the Society, a fundraising campaign to assist in the payoff of ASCPT’s historic office building in Old Town, Alexandria, VA, and efforts to remodel it to create meeting space for ASCPT member meetings.

Phase one of this campaign involves raising enough funds to pay off the existing mortgage on the Society’s office building. Step two in the campaign is renovating the existing space and converting it to a first-rate conference space to accommodate ASCPT members meetings like the Scientific Program Committee, the CPT, PSP, and CTS editorial team meetings, Board Meetings, and other member gatherings. The space will undergo a significant renovation to include creating a state-of-the-art conference space, with leapfrog technology.

Help your Society meet our fundraising goals by making a donation safely and securely online at www.ascpt.org. Questions about the Make It Ours, Make It Great campaign can be directed to Sharon Swan at sharon@ascpt.org.

ASCPT thanks our members who have already made contributions to this important fundraising effort.

**New Member**

Christopher Vinnard, MD, MPH, MSCE, Assistant Professor, Public Health Research Institute, New Jersey Medical School, Newark, NJ

Dr. Sean Hennessy encouraged Dr. Vinnard to join ASCPT. Dr. Vinnard completed his clinical fellowship in adult infectious diseases at the Center for Pharmacoepidemiology Research and Training at the University of Pennsylvania where Dr. Hennessy serves as director. Along with his research training in pharmacoepidemiology, Dr. Vinnard attended the Annual Meeting during his fellowship. Conversations with Dr. Hennessy and his own experiences at the Annual Meeting convinced him that ASCPT would provide the best fit for his research interests and career development.

The interdisciplinary nature of the ASCPT community was a key factor in Dr. Vinnard’s decision to build his professional network within the Society. As an infectious disease physician scientist, he looks forward to connecting with investigators across the entire spectrum of biomedical science, from discovery to therapeutic applications. He also looks forward to building relationships with researchers with a wide range of...
clinical expertise. These types of interactions, especially ones outside of his “comfort zone,” can lead to novel hypotheses and novel applications of research methods within his chosen field.

The ability to apply mathematical tools to address clinical questions is one of the most interesting aspects of Dr. Vinnard’s work in clinical pharmacology and translational medicine. His current work is supported by a National Institutes of Health Career Development Award. In this work, he is completing research training in pharmacometrics, with a particular focus on HIV-associated tuberculosis. His goal is to apply the tools of pharmacokinetic modeling and simulation to identify the patient factors that relate to treatment failure or toxicity as a consequence of that pharmacokinetic variability.

One of the questions that often comes up in practice is the appropriate use of therapeutic drug monitoring during the clinical follow-up of patients undergoing combination treatment for active tuberculosis. His training in the area of antituberculosis drug pharmacokinetics has informed conversations that Dr. Vinnard has had with patients as well as tuberculosis clinicians regarding these types of treatment decisions.

Dr. Vinnard is interested in the regulation of drug transporters involved in antituberculosis drug distributions and elimination, particularly in response to the inflammatory stimuli that are typical of HIV-associated immune activation. His interest bears in mind the goal of global elimination of tuberculosis that will require optimization of currently available therapies. A project currently under development is to understand the drug transporters in the distribution of antituberculosis drugs across the blood-CSF barrier.

Member Spotlight

Guy-Armel Bounda, BSc, MSc, PhD, Biomedical Advisor and Drug Expert at SINOMEDICA CO., Ltd. Nanjing, China

In 2012, Dr. Bounda decided to join ASCPT in order to learn and enhance his clinical and academic skills and competencies. He believes ASCPT is a scientific society that can help shape many areas of his career. He views ASCPT as a strong scientific society that promotes the aim of clinical pharmacology and translational medicine by sharing and publishing clinical knowledge through multiple channels. He believes strongly that understanding the principles of clinical pharmacology is the basis of safe and effective therapeutic practice, and joining ASCPT has been a critical part of his medical knowledge. He learned about ASCPT through CPT while he was pursuing his PhD in clinical pharmacology at China Pharmaceutical University (Jiangsu, Nanjing). He came to understand the Society in its variety of areas while researching published papers as he completed his laboratory benchwork. Dr. Bounda’s focus is more in the arena of clinical pharmacy, but he feels that clinical pharmacologists and pharmacists are accountable to the same target groups and this has helped give him a firm grounding in the principles of drug therapy.

Joining ASCPT has “showered” Dr. Bounda with many opportunities to learn and share scientific knowledge with other clinical professionals through several volunteer opportunities within the Society. He feels his membership allows him to connect with great scientists through the wide range of activities offered by the Society. As a young scientist, Dr. Bounda sees his membership as allowing him to grow and stay professionally active. His favorite aspect of membership is the journal family. He has learned a lot from the journals. He also attended the Annual Meeting in New Orleans where he was able to present a poster and discover a lot that increased his curiosity.

Dr. Bounda has observed that clinical pharmacists and clinical pharmacologists share a common goal even though they approach that goal from differing perspectives and educational backgrounds. He believes that one of the most interesting things in clinical pharmacology is that it is constantly moving forward fast. Clinical pharmacology is involved with optimal use of current medications including the evaluation of their safety and efficacy and development of new and improved pharmacotherapy. To the younger generation of the field, Dr. Bounda encourages them to fully participate in the Society regardless of their clinical specialties, and feels that that they will learn a lot in doing so. Being active and energetic healthcare professionals and regard for the key issue of professional success are often enjoyable key features of being a clinical pharmacologist.

Dr. Bounda has observed that clinical pharmacists and clinical pharmacologists share a common goal even though they approach that goal from differing perspectives and educational backgrounds. He believes that one of the most interesting things in clinical pharmacology is that it is constantly moving forward fast. Clinical pharmacology is involved with optimal use of current medications including the evaluation of their safety and efficacy and development of new and improved pharmacotherapy. To the younger generation of the field, Dr. Bounda encourages them to fully participate in the Society regardless of their clinical specialties, and feels that that they will learn a lot in doing so. Being active and energetic healthcare professionals and regard for the key issue of professional success are often enjoyable key features of being a clinical pharmacologist.

Dr. Bounda has participated in multiple ASCPT webinars and assisted as a working volunteer for the Asparagus Kinetic Project at the ASCPT 2015 Annual Meeting.
Wendy S. Putnam, PhD, Senior Scientist, Genentech, South San Francisco, CA

In 2003, Dr. Putnam was a Presidential Trainee Award recipient. This honor introduced her to the field of clinical pharmacology and translational medicine. That year she presented a poster of her research at the Annual Meeting and met many clinical pharmacologists who shared her interest in drug development. Later that year she joined ASCPT. Dr. Putnam worked for three years in preclinical pharmacokinetics following her graduate studies. Her work supported molecules in development from late-stage research to phase I. When she had the opportunity she followed the molecule into clinical development and has worked in clinical pharmacology ever since. She feels that for the past 12 years she has continued to find inspiration from her colleagues and to learn from them.

As an undergraduate, Dr. Putnam’s interests in science and mathematics led her to chemical engineering. However, she was searching for a medical application for her studies. She decided to pursue a master’s degree in materials science, which she planned to apply to developing medical devices. After completing her master’s degree with a focus on polymer science, she went to work for a company that developed transdermal delivery systems. After working in formulations and process engineering for three years she realized that she was more interested in the drug in the patch than the adhesive she was working on. She enrolled in a graduate program at UCSF in pharmaceutical chemistry, where she had the opportunity to conduct a clinical study to investigate the effect of MDR1 genotypes on dicloxacillin pharmacokinetics. After receiving her PhD, she took a scientist position at a biotechnology company. She worked for three years in early development PK before transitioning to clinical pharmacology.

Dr. Putnam’s favorite aspect of ASCPT membership is the journals. She singles out CPT as helping her stay current in the field. She explains that she likes the online access to the journal as well as a quick reference, but she still enjoys having a print version in her mailbox every month.

ASCPT impacts the field in many ways. Dr. Putnam explains that ASCPT fosters collaborations and innovation by bringing people together across disciplines to share and process information and discuss issues from different perspectives. The Society offers learning opportunities through the Annual Meeting, journals, and webinars to help both young scientists in developing their expertise early in their careers and experienced clinical pharmacologists in staying current in the field. Dr. Putnam describes ASCPT as “a community and a collective voice for clinical pharmacologists that helps shape the direction of the field.”

Dr. Putnam advises young people to find mentors in ASCPT who are working in a variety of areas to help them learn about the breadth of opportunities that are available to them in clinical pharmacology and translational medicine. She explains that if one is interested in drug development, one could gain exposure to large and small companies, small molecules and biologics, early- and late-stage development, and modeling and simulation. She also advises the younger generation to attend the Annual Meeting and to look for ways to volunteer in the organization. Service will help develop leadership skills and a network of colleagues in the field. She goes on to encourage them to follow her example and present their work at the Annual Meeting. She believes “getting involved in ASCPT will help them to continue to learn and grown and make their professional lives more fulfilling by being part of a larger scientific community.”

Dr. Putnam has been a member of ASCPT since 2003.

Sonja Hartmann, PhD, Postdoctoral Associate, University of Florida, Department of Pharmacology, Orlando, FL

After finishing her studies in biology, Dr. Hartmann earned her PhD in Pharmacology in Germany at the University of Wuerzburg. During her time at the University of Wuerzburg she had extensive exposure to research in cardiovascular, renal, and immunological diseases. While her studies during her PhD work mainly focused on basic experimental research, she started to realize that she wanted to work in a field with a direct impact on patients. With this desire in mind, pharmacometrics sounded to her like the ideal field where she could apply her knowledge of biology and disease processes to help develop and improve therapies for patients. She counts herself fortunate for the opportunity to do her postdoc training at the University of Florida at the Center for Pharmacometrics and Systems Pharmacology,
which really helped her get her foot in the door in the field of clinical pharmacology.

Dr. Hartmann is particularly interested in quantitative pharmacology, especially pharmacometrics and systems pharmacology, and the attempt to describe pharmacokinetics, pharmacodynamics, and disease progression via mathematical/computational models. In her opinion, pharmacometrics and systems pharmacology provide important tools for the drug development process by helping to optimize clinical trial design, predicting adverse events, and overall helping understand physiological processes better. In short, pharmacometrics and systems pharmacology is about bringing better therapeutics to the patient.

ASCPT provides a great platform to connect to peers in clinical pharmacology and translational medicine. Dr. Hartmann feels that ASCPT also provides the opportunity to learn and stay up-to-date on the latest and greatest research and advances in the field. She really appreciates the effort that is made by ASCPT to integrate students and trainees and give them the opportunity to establish themselves in the field of clinical pharmacology.

Dr. Hartmann became a member of ASCPT in 2015. In addition to having attended the Annual Meeting, Dr. Hartmann was a 2016 recipient of a Presidential Trainee Award.

International Profile

Adam F. Cohen, MD, PhD, CEO, Centre for Human Drug Research, Leiden, Netherlands

The Netherlands is a country with a population slightly larger than the greater New York area. Dr. Cohen explains that the scientific output of the Netherlands is consistently in the top fifth of the world (normalized for population). The Netherlands has a lively and very active Clinical Pharmacology scene that has been largely untouched by the dispute about who the clinical pharmacologist is (pharmacist vs. physician, internist vs. general practitioner). The country is ideally placed for translational research, with a unique capability for hospital pharmacies to produce GMP medicines. All eight university medical centers are fully equipped with advanced laboratory and imaging facilities. There has also been a large increase in the collaborative spirit in the country in trials and also technology development with the technical universities in Delft and Twente. According to Dr. Cohen, most Dutch clinical pharmacologists are members of ASCPT and actively participate in the Annual Meeting. ASCPT serves as an important channel for the international aspirations of Dutch researchers. Dr. Cohen points out that “a small country can only act internationally!”

Dr. Cohen trained as a pharmacist and a physician in Leiden, but he received his clinical pharmacological training at the Wellcome Research Labs in Beckenham. His mentors were Tony Peck and Arthur Fowle. At a very young age, Dr. Cohen was responsible for the development of lamotrigine and tPA. Following his training, he returned to the Netherlands to set up the Centre for Human Drug Research (CHDR). Now, 30 years later, CHDR is the biggest early drug development organization in the country. CHDR may not have a direct impact on patient care, but they teach 300 new doctors each year and are involved in all clinical courses. CHDR’s TRC-pharmacology app has been downloaded over 200,000 times and helps in educating doctors worldwide.

ASCPT membership for Dr. Cohen and his colleagues highlights their international orientation and *CPT* is an important channel, although as the Editor-in-Chief of the British Journal of Clinical Pharmacology he feels a little healthy competition with *CPT*.

After 35 years in the field, Dr. Cohen believes that the development of new healthcare interventions is probably one of the most exciting areas to be in for a recent medical, pharmaceutical, or science graduate. CHDR has many international fellows, but few from the United States — they welcome applications!

Dr. Cohen has been a member of ASCPT since 1989.

Welcome New ASCPT Members!

Wael Alghamdi, PharmD
University of Florida

Gautam Baheti, PhD
CSL Behring

Stephen Balevic, MD
Duke University Medical Center

Waldo Belloso, PhD
Hospital Italiano de Buenos Aires School of Medicine

Michael Block, PhD
Bayer AG

David Boulton, PhD
AstraZeneca

ChienWei Chiang, PhD
IUPUI

Charles Cohen, PhD
Xenon Pharmaceuticals, Inc.

Sinziana Cristea
Leiden University

Lei Diao, PhD
Janssen China R&D

Katarzyna Drozda, PharmD
US Food and Drug Administration

Reem Elbekai, BPharm, PhD
Otsuka